Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC S versus LOPRESSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC S versus LOPRESSOR.
BETOPTIC S vs LOPRESSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
Instill 1 drop in the affected eye(s) twice daily.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Category C
Category C
Beta-Blocker
Beta-Blocker